TECH Looks 1.7% Overvalued on GF Value™

gurufocus.com · 2026-09-23

On September 23, 2026, Bio-Techne Corp (NASDAQ: TECH) announced that its shareholders approved the acquisition agreement with Merck KGaA, advancing the transact

TickrTrends take: # TECH Valuation Analysis TECH is currently assessed as undervalued by TickrTrends, which creates a notable divergence from the GF Value model's assessment of overvaluation. A valuation-focused reader should monitor whether this gap narrows or widens, as it may indicate either a timing opportunity or a sign that one of the models requires recalibration based on the company's healthcare sector fundamentals. The tension between these two valuations suggests investors should examine the underlying assumptions driving each assessment before making decisions.

Read the full story at gurufocus.com →